Publication Cover
Neurological Research
A Journal of Progress in Neurosurgery, Neurology and Neurosciences
Volume 39, 2017 - Issue 7
513
Views
15
CrossRef citations to date
0
Altmetric
Original Research Paper

Neuroprotective effect of melatonin on soluble Aβ1–42-induced cortical neurodegeneration via Reelin–Dab1 signaling pathway

, , , , , & show all
Pages 621-631 | Received 31 May 2016, Accepted 23 Mar 2017, Published online: 07 Apr 2017
 

Abstract

Objective: Soluble Aβ1–42 oligomers play a vital role in the development and pathogenesis of Alzheimer’s disease (AD). Melatonin could delay the progress of AD through multiple mechanisms. Reelin–Dab1 signaling plays an important role in AD, including neuronal function and synaptic plasticity. However, whether melatonin could exert its neuroprotective function against soluble Aβ1–42-induced neurotoxicity during AD development through regulating Reelin–Dab1 signaling remains poorly understood.

Methods: AD rat model was established by soluble Aβ1–42 repeated intracerebroventricular injection. Using immunohistochemistry and Western blot analyses, the effect of melatonin on synaptic plasticity, neuritic degeneration, and astrocyte activation was investigated in cerebral cortex. Meanwhile, the expression of Reelin and Dab1 was also examined in cerebral cortex. In our in vitro study, Reelin–Dab1 signaling was inhibited by Reelin antibody, and neuroprotective effect of melatonin against Aβ1–42 was further determined.

Results: Melatonin ameliorated the neurotoxiciy and astrocyte activation induced by Aβ1–42 in the cerebral cortex. Melatonin also blocked the reduction in Reelin and Dab1 expression induced by Aβ1–42. Using in vitro study, Reelin inactivation completely abolished the protective effect of melatonin against Aβ1–42-induced neurotoxicity.

Discussion: Melatonin might play its neuroprotective role against Aβ1–42 through mediating Reelin–Dab1 signaling pathway. Melatonin could be a safe and remarkable therapeutic candidate for AD and other aged-associated neurodegenerative diseases.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.